

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not, and is not intended to, constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdiction. The Offer Shares have not been and will not be registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”) or securities law of any state or other jurisdiction of the United States and may not be offered, sold, pledged or otherwise transferred within the United States, except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws. There will be no public offer of the Offer Shares in the United States. The Offer Shares are being offered and sold solely (1) to qualified institutional buyers as defined in Rule 144A under the U.S. Securities Act pursuant to an exemption from registration under the U.S. Securities Act; and (2) outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act and applicable laws of each jurisdiction where those offers and sales occur.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the prospectus dated December 31, 2025 (the “**Prospectus**”) issued by Suzhou Ribo Life Science Co., Ltd. (蘇州瑞博生物技術股份有限公司) (the “**Company**”) for detailed information about the Global Offering described below before deciding whether or not to invest in the H Shares thereby being offered. The Company has not been and will not be registered under the U.S. Investment Company Act of 1940, as amended.

Unless otherwise defined in this announcement, capitalized terms used herein shall have the same meanings as those defined in the Prospectus.

In connection with the Global Offering, China International Capital Corporation Hong Kong Securities Limited as stabilizing manager (the “**Stabilizing Manager**”) (or its affiliates or any person acting for it) on behalf of the Underwriters, to the extent permitted by the applicable laws and regulatory requirements of Hong Kong or elsewhere, may make purchases, over-allocate or effect transactions in the market or otherwise take such stabilizing action(s) with a view to stabilizing or supporting the market price of the H Shares at a level higher than that which might otherwise prevail for a limited period after the Listing Date. However, there is no obligation on the Stabilizing Manager (or its affiliates or any person acting for it) to conduct any such stabilizing action. Such stabilizing action, if taken, (a) will be conducted at the absolute discretion of the Stabilizing Manager (or its affiliates or any person acting for it) and in what the Stabilizing Manager reasonably regards as the best interest of the Company, (b) may be discontinued at any time and (c) is required to be brought to an end within 30 days after the last day for lodging applications under the Hong Kong Public Offering.

Potential investors should note that no stabilizing action can be taken to support the price of the H Shares for longer than the stabilization period, which will begin on the Listing Date and is expected to expire on Thursday, February 5, 2026, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. After this date, when no further stabilizing action may be taken, demand for the H Shares, and therefore the price of the H Shares, could fall.

The obligations of the Hong Kong Underwriters under the Hong Kong Underwriting Agreement to subscribe for, and to procure subscribers for, the Hong Kong Offer Shares, are subject to termination by the Overall Coordinators (for themselves and on behalf of the Underwriters) if certain events shall occur prior to 8:00 a.m. on the Listing Date. Such grounds are set out in the section headed “Underwriting” in the Prospectus. It is important that you refer to that section for further details.



Suzhou Ribo Life Science Co., Ltd.
蘇州瑞博生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

GLOBAL OFFERING

Number of Offer Shares under the Global Offering	: 31,610,400 H Shares (taking into account the full exercise of the Offer Size Adjustment Option and subject to the Over-allotment Option)
Number of Hong Kong Offer Shares	: 2,748,800 H Shares
Number of International Offer Shares	: 28,861,600 H Shares (taking into account the full exercise of the Offer Size Adjustment Option and subject to the Over-allotment Option)
Offer Price	: HK\$57.97 per Offer Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and Hong Kong Stock Exchange trading fee of 0.00565%
Nominal value	: RMB1.00 per H Share
Stock code	: 6938

*Joint Sponsors, Overall Coordinators, Joint Global Coordinators, Joint Bookrunners,
Joint Lead Managers*



Overall Coordinators, Joint Global Coordinators, Joint Bookrunners, Joint Lead Managers

ABCI 農銀國際 中銀國際 BOCI ICBC 工銀國際 MACQUARIE

Joint Global Coordinator, Joint Bookrunner, Joint Lead Manager



Joint Bookrunner, Joint Lead Manager



SUZHOU RIBO LIFE SCIENCE CO., LTD.
蘇州瑞博生物技術股份有限公司

ANNOUNCEMENT OF ALLOTMENT RESULTS

*Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated December 31, 2025 (the “**Prospectus**”) issued by Suzhou Ribo Life Science Co., Ltd. (蘇州瑞博生物技術股份有限公司) (the “**Company**”).*

Warning: In view of high concentration of shareholding in a small number of Shareholders, Shareholders and prospective investors should be aware that the price of the H Shares could move substantially even with a small number of H Shares traded and should exercise extreme caution when dealing in the H Shares.

SUMMARY

Company information	
Stock code	6938
Stock short name	RIBOLIFE-B
Dealings commencement date	January 9, 2026*

* see note at the end of the announcement

Price Information	
Fixed Offer Price	HK\$57.97
Offer Shares and Share Capital	
Number of Offer Shares	31,610,400 H Shares
Final Number of Offer Shares in Hong Kong Public Offering	2,748,800 H Shares
Final Number of Offer Shares in International Offering (taking into account the full exercise of the Offer Size Adjustment Option and subject to the Over-allotment Option)	28,861,600 H Shares
Number of issued shares upon Listing (before any exercise of the Over-allotment Option)	165,813,510 Shares

The number of Offer Shares above is determined after taking into account the additional shares issued under the following Offer Size Adjustment Option.

Offer Size Adjustment Option (Upsize option)	
Number of additional shares issued under the option	4,123,000 H Shares
– International Offering	4,123,000 H Shares
Over-allocation	
No. of Offer Shares over-allocated	4,741,400 H Shares
– International Offering	4,741,400 H Shares
Such over-allocation may be covered by exercising the Over-allotment Option or by making purchases in the secondary market at prices that do not exceed the Offer Price or a combination of these means. In the event the Over-allotment Option is exercised, an announcement will be made on the Stock Exchange's website.	
Proceeds	
Gross proceeds (Note)	HK\$1,832.45 million
Less: Estimated listing expenses payable based on the Offer Price	HK\$130.65 million
Net proceeds	HK\$1,701.80 million
Note: Gross proceeds refer to the amount to which the issuer is entitled to receive. For details of the use of proceeds, please refer to the Prospectus dated December 31, 2025.	

ALLOTMENT RESULTS DETAILS

HONG KONG PUBLIC OFFERING

No. of valid applications	42,771
No. of successful applications	5,367
Subscription level	101.06 times
Claw-back triggered	N/A
No. of Offer Shares initially available under the Hong Kong Public Offering	2,748,800 H Shares
No. of Offer Shares reallocated from the International Offering (claw-back)	0
Final no. of Offer Shares under the Hong Kong Public Offering	2,748,800 H Shares
% of Offer Shares under the Hong Kong Public Offering to the Global Offering	8.7%

Note: For details of the final allocation of shares to the Hong Kong Public Offering, investors can refer to <https://www.eipo.com.hk/eIPOAllotment> to perform a search by identification number or <https://www.eipo.com.hk/eIPOAllotment> for the full list of allottees.

INTERNATIONAL OFFERING

No. of placees	177
Subscription Level	16.7 times
No. of Offer Shares initially available under the International Offering	24,738,600 H Shares
No. of Offer Shares reallocated to the Hong Kong Public Offering (claw-back)	0
Final no. of Offer Shares under the International Offering (taking into account the full exercise of the Offer Size Adjustment Option)	28,861,600 H Shares
% of Offer Shares under the International Offering to the Global Offering	91.3%

*The Directors confirm that, to the best of their knowledge, information and belief, save for a consent under paragraph 1C(2) of Appendix F1 to the Listing Rules (the “**Placing Guidelines**”) granted by the Stock Exchange to permit the Company to allocate certain Offer Shares in the International Offering to close associates of existing Shareholders of the Company, (i) none of the Offer Shares subscribed by the placees and the public have been financed directly or indirectly by the Company, any of the Directors, chief executive of the Company, Supervisors, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates; and (ii) none of the placees and the public who have purchased the Offer Shares are accustomed to taking instructions from the Company, any of the Directors, chief executive of the Company, Supervisors, controlling Shareholders, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of Shares registered in his/her/its name or otherwise held by him/her/it.*

*Erik Selin Fastigheter Aktiebolag (“**Erik Selin Fastigheter AB**”) is a substantial shareholder of Ribocure AB, a subsidiary of the Company. Therefore, Erik Selin Fastigheter AB is a core connected person of the Company. The Company has applied for, and the Stock Exchange has granted, a waiver from strict compliance with Rule 9.09(b) of the Listing Rules to permit Erik Selin Fastigheter AB to participate as a cornerstone investor in the Global Offering. For details, please refer to the section headed “Waiver From Strict Compliance with the Listing Rules and Exemption From Strict Compliance with the Companies (Winding Up and Miscellaneous Provisions) Ordinance – Waiver From Strict Compliance with Rule 9.09(b) of the Listing Rules in relation to Cornerstone Subscription by a Core Connected Person” in the Prospectus.*

The places in the International Offering include the following:

Cornerstone Investors

Investor ⁽¹⁾	Number of Offer Shares allocated	% of Offer Shares ⁽²⁾	% of total issued H Shares after the Global Offering ⁽²⁾	% of total issued share capital after the Global Offering ⁽²⁾	Existing shareholders or their close associates
Arc Avenue Asset Management Pte. Ltd.	671,000	2.1%	0.4%	0.4%	No
Bright Stone Holdings Limited	536,800	1.7%	0.3%	0.3%	No
China Asset Management Co., Ltd.	2,013,200	6.4%	1.2%	1.2%	No
Da Cheng International Asset Management Company Limited and Dacheng Fund Management Company Limited	2,013,200	6.4%	1.2%	1.2%	No
Erik Selin Fastigheter Aktiebolag	1,342,000	4.2%	0.8%	0.8%	No ⁽³⁾
Himension Fund	1,342,000	4.2%	0.8%	0.8%	No
IvyRock Asset Management (HK) Limited	536,800	1.7%	0.3%	0.3%	No
Mingxin Growth Ventures LS2 Limited	1,342,000	4.2%	0.8%	0.8%	No
Springs Capital (Hong Kong) Limited	1,342,000	4.2%	0.8%	0.8%	No
Taikang Life Insurance Co., Ltd.	1,610,400	5.1%	1.0%	1.0%	No
Tenbagger Capital Nengxin), LP. (上海拾貝能信私募基金管理合夥企業(有限合夥)), Tenbagger Capital (Shanghai, Ziran), LP. (上海自然拾貝投資管理合夥企業(有限合夥)) and Huatai Capital Investment Limited	671,000	2.1%	0.4%	0.4%	No
Total	13,420,400	42.5%	8.1%	8.1%	

Notes:

- (1) For further details of the Cornerstone Investors, please refer to the section headed “Cornerstone Investors” in the Prospectus.
- (2) Taking into account the full exercise of the Offer Size Adjustment Option and before any exercise of the Over-allotment Option.
- (3) Erik Selin Fastigheter Aktiebolag (“**Erik Selin Fastigheter AB**”) is a substantial shareholder of Ribocure AB, a subsidiary of the Company. Therefore, Erik Selin Fastigheter AB is a core connected person of the Company. The Company has applied for, and the Stock Exchange has granted, a waiver from strict compliance with Rule 9.09(b) of the Listing Rules to permit Erik Selin Fastigheter AB to participate as a cornerstone investor in the Global Offering. For details, please refer to the section headed “Waiver From Strict Compliance with the Listing Rules and Exemption From Strict Compliance with the Companies (Winding Up and Miscellaneous Provisions) Ordinance – Waiver From Strict Compliance with Rule 9.09(b) of the Listing Rules in relation to Cornerstone Subscription by a Core Connected Person” in the Prospectus.

Allotees with Waivers/Consents Obtained

Investor	Number of Offer Shares allocated	% of Offer Shares⁽¹⁾	% of total issued H Shares after the Global Offering⁽¹⁾	% of total issued share capital after the Global Offering⁽¹⁾	Relationship
Allotees with consent under paragraph 1C(2) of the Placing Guidelines in relation to subscription for Offer Shares by existing Shareholders and close associates of existing Shareholders ⁽²⁾					
William WONG (王興國)	402,600	1.27%	0.24%	0.24%	An existing Shareholder and a placee
Worldstar Global Holdings Limited	67,000	0.21%	0.04%	0.04%	An existing Shareholder and a placee
Blue Bay Healthcare Anchor Fund SPC	336,000	1.06%	0.20%	0.20%	A close associate of an existing Shareholder and a placee
Allotees with consent under paragraph 1C(1) of the Placing Guidelines in relation to allocations to connected clients ⁽²⁾					
CICC Financial Trading Limited (in connection with Zhonghe OTC Swaps) ⁽³⁾	671,000	2.12%	0.40%	0.40%	Each is a connected client of China International Capital Corporation Hong Kong Securities Limited and a placee
CICC Financial Trading Limited (in connection with Yongjin OTC Swaps) ⁽³⁾	40,000	0.13%	0.02%	0.02%	
CICC Financial Trading Limited (in connection with Minghong OTC Swaps) ⁽³⁾	13,400	0.04%	0.01%	0.01%	
CICC Financial Trading Limited (in connection with Wangzheng OTC Swaps) ⁽³⁾	1,200	0.00%	0.00%	0.00%	

Notes:

- (1) Taking into account the full exercise of the Offer Size Adjustment Option and before any exercise of the Over-allotment Option.
- (2) For details of (i) the consent under paragraph 1C(2) of the Placing Guidelines granted by the Stock Exchange to permit the Company to allocate certain Offer Shares in the International Offering to close associates of existing Shareholders, and (ii) the consent under paragraph 1C(1) of the Placing Guidelines in relation to allocations to connected clients, please refer to the section headed “Waivers From Strict Compliance with the Listing Rules and exemption from Strict Compliance with the Companies (Winding Up and Miscellaneous Provisions) Ordinance” in the Prospectus and the section headed “Other Information” in this announcement.
- (3) As defined in the section headed “Other Information – Placing to connected clients with prior consent under paragraph 1C(1) of the Placing Guidelines” in this announcement.

Investor	Number of Offer Shares allocated	% of Offer Shares ⁽¹⁾	% of total issued H Shares after the Global Offering ⁽¹⁾	% of total issued share capital after the Global Offering ⁽¹⁾	Relationship
Guotai Junan Investments (Hong Kong) Limited	274,600	0.87%	0.17%	0.17%	A connected client of Guotai Junan Securities (Hong Kong) Limited and HAITONG INTERNATIONAL SECURITIES COMPANY LIMITED, and a placee
ABCI Asset Management Limited	5,800	0.02%	0.00%	0.00%	A connected client of ABCI Capital Limited and ABCI Securities Company Limited and a placee
ICBC UBS Asset Management Co., Ltd.	94,000	0.30%	0.06%	0.06%	Each is a connected client of ICBC International Securities Limited and a placee
Invesco Great Wall Fund Management Co., Ltd.	6,600	0.02%	0.00%	0.00%	
Fullgoal Fund Management CO. LTD	100,600	0.32%	0.06%	0.06%	Each is a connected client of Guotai Junan Securities (Hong Kong) Limited and HAITONG INTERNATIONAL SECURITIES COMPANY LIMITED, and a placee
Fullgoal Asset management (HK) Limited	100,600	0.32%	0.06%	0.06%	
HAITONG INTERNATIONAL ASSET MANAGEMENT (HK) LIMITED	6,600	0.02%	0.00%	0.00%	

LOCK-UP UNDERTAKINGS

Pre-IPO Investors (as defined in the “History and Corporate Structure” section of the Prospectus)

Name	Number of shares held in the Company subject to lock-up undertakings upon Listing	Number of H Shares held in the Company subject to lock-up undertakings upon Listing	% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing ⁽¹⁾	% of shareholding in the Company subject to lock-up undertakings upon Listing ⁽¹⁾	Last day subject to the lock-up undertakings ⁽²⁾
Future Industry Investment Fund (Limited Partnership) (先進製造產業投資基金(有限合夥))	11,430,002	11,430,002	6.89%	6.89%	January 8, 2027
Ningbo Panlin Qianyuan Equity Investment Partnership (Limited Partnership) (寧波磐霖仟源股權投資合夥企業(有限合夥))	4,380,906	4,380,906	2.64%	2.64%	January 8, 2027
Hangzhou Panlin Xukang Venture Capital Partnership (Limited Partnership) (杭州磐霖旭康創業投資合夥企業(有限合夥))	1,175,724	1,175,724	0.71%	0.71%	January 8, 2027
Jiaxing Panlin Guangci Venture Capital Partnership (Limited Partnership) (嘉興磐霖廣慈創業投資合夥企業(有限合夥))	1,004,334	1,004,334	0.61%	0.61%	January 8, 2027
Jiaxing Panlin Yuesheng Venture Capital Partnership (Limited Partnership) (嘉興磐霖悅生創業投資合夥企業(有限合夥))	817,455	817,455	0.49%	0.49%	January 8, 2027
Shanghai Panlong Venture Capital Partnership (Limited Partnership) (上海磐隴創業投資合夥企業(有限合夥))	817,455	817,455	0.49%	0.49%	January 8, 2027
Qingdao Panlin Hongyu Venture Capital Partnership (Limited Partnership) (青島磐霖鴻裕創業投資企業(有限合夥))	782,695	782,695	0.47%	0.47%	January 8, 2027
Wise Vigour Limited	8,714,881	8,714,881	5.26%	5.26%	January 8, 2027
Kunshan Industrial Technology Research Institute of Small Nucleic Acid Biotechnology Research Institute Co. Ltd. (昆山市工業技術研究院小核酸生物技術研究所有限責任公司)	3,224,973	3,224,973	1.94%	1.94%	January 8, 2027
Kunshan Hi-tech Venture Investment Co., Ltd. (昆山高新創業投資有限公司)	2,553,454	2,553,454	1.54%	1.54%	January 8, 2027

Name	Number of shares held in the Company subject to lock-up undertakings upon Listing	Number of H Shares held in the Company subject to lock-up undertakings upon Listing	% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing ⁽¹⁾	% of shareholding in the Company subject to lock-up undertakings upon Listing ⁽¹⁾	Last day subject to the lock-up undertakings ⁽²⁾
Kunshan Guoke Venture Capital Co., Ltd. (昆山市國科創業投資有限公司)	1,877,862	1,877,862	1.13%	1.13%	January 8, 2027
Kunshan Gongyan Venture Investment Co. Ltd. (昆山市工研創業投資有限公司)	816,246	816,246	0.49%	0.49%	January 8, 2027
Ionis Pharmaceuticals, Inc.	7,634,247	7,634,247	4.60%	4.60%	January 8, 2027
Shenzhen Yilong Venture Capital L.P. (深圳翼龍創業投資合夥企業(有限合夥))	6,297,338	6,297,338	3.80%	3.80%	January 8, 2027
Suzhou Jiyuan Yuanxing Equity Investment L.P. (蘇州紀源源星股權投資合夥企業(有限合夥))	5,239,889	5,239,889	3.16%	3.16%	January 8, 2027
Tianjin Haihe Asymchem Biopharmaceutical Industry Innovation Investment L.P. (天津海河凱萊英生物醫藥產業創新投資基金(有限合夥))	1,949,716	1,949,716	1.18%	1.18%	January 8, 2027
Trinity Zhongzhi (Tianjin) Venture Capital Center L.P. (三一眾志(天津)創業投資中心(有限合夥))	878,766	878,766	0.53%	0.53%	January 8, 2027
Trinity Zhongzhi II (Tianjin) Venture Capital Center L.P.(三一眾志二期(天津)創業投資中心(有限合夥))	537,055	537,055	0.32%	0.32%	January 8, 2027
Trinity UCSF Limited	347,418	347,418	0.21%	0.21%	January 8, 2027
TIF Biomedical Fund II VCC	358,036	358,036	0.22%	0.22%	January 8, 2027
CICC Qide (Xiamen) Innovation Biomedical Venture Capital Partnership (Limited Partnership) (中金啟德(廈門)創新生物醫藥創業投資合夥企業(有限合夥))	2,091,741	2,091,741	1.26%	1.26%	January 8, 2027
Ningbo Meishan Bonded Port District Qirui Equity Investment L.P. (寧波梅山保稅港區祺睿股權投資中心(有限合夥))	983,629	983,629	0.59%	0.59%	January 8, 2027
China Resources Venture Investment Co., Ltd. (華潤創業投資有限公司)	2,133,099	2,133,099	1.29%	1.29%	January 8, 2027

Name	Number of shares held in the Company subject to lock-up undertakings upon Listing	Number of H Shares held in the Company subject to lock-up undertakings upon Listing	% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing ⁽¹⁾	% of shareholding in the Company subject to lock-up undertakings upon Listing ⁽¹⁾	Last day subject to the lock-up undertakings ⁽²⁾
Shanghai Yangtze River Delta Industrial Upgrading Equity Investment L.P. (上海長三角產業升級股權投資合夥企業(有限合夥))	1,969,908	1,969,908	1.19%	1.19%	January 8, 2027
Mr. LIU Guoping (劉國平)	1,899,525	1,899,525	1.15%	1.15%	January 8, 2027
Jiaying Futong Investment L.P. (嘉興福通投資合夥企業(有限合夥))	1,881,880	1,881,880	1.13%	1.13%	January 8, 2027
Jinan Mingxin Industrial Investment Fund Partnership (Limited Partnership) (濟南名信產業投資基金合夥企業(有限合夥))	1,864,127	1,864,127	1.12%	1.12%	January 8, 2027
Zhuhai Qiheng Equity Investment L.P. (珠海騏恒投資合夥企業(有限合夥))	1,852,159	1,852,159	1.12%	1.12%	January 8, 2027
Wenzhou Chouqin Borui Venture Investment L.P. (溫州酬勤博瑞創業投資合夥企業)	1,318,973	1,318,973	0.80%	0.80%	January 8, 2027
Tianjin Chouqin Tiancheng Venture Investment L.P. (天津酬勤天成創業投資合夥企業)	338,302	338,302	0.20%	0.20%	January 8, 2027
Xizang Xingfan Enterprise Management Co., Ltd. (西藏星帆企業管理有限公司)	687,302	687,302	0.41%	0.41%	January 8, 2027
Wuxi Xingxi Venture Capital Partnership (Limited Partnership) (無錫星錫創業投資合夥企業(有限合夥))	867,471	867,471	0.52%	0.52%	January 8, 2027
Jiaying Co-way Yintian Venture Capital L.P. (嘉興眾匯銀田創業投資合夥企業(有限合夥))	1,045,869	1,045,869	0.63%	0.63%	January 8, 2027
Jiaying Xiangtian Venture Capital L.P. (嘉興象田創業投資合夥企業(有限合夥))	367,026	367,026	0.22%	0.22%	January 8, 2027
Ningbo Daxie Yungong Jiajie Equity Investment Partnership (Limited Partnership) (寧波大榭允公嘉傑股權投資合夥企業(有限合夥))	1,367,837	1,367,837	0.82%	0.82%	January 8, 2027

Name	Number of shares held in the Company subject to lock-up undertakings upon Listing	Number of H Shares held in the Company subject to lock-up undertakings upon Listing	% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing ⁽¹⁾	% of shareholding in the Company subject to lock-up undertakings upon Listing ⁽¹⁾	Last day subject to the lock-up undertakings ⁽²⁾
Shanghai Zhulu Enterprise Management Consultation Center L.P. (上海築陸企業管理諮詢中心(有限合夥))	1,181,943	1,181,943	0.71%	0.71%	January 8, 2027
Zhuhai Qidi Rongchuang I Medical Industry Investment L.P.(珠海啟迪融創一期醫療產業投資合夥企業(有限合夥))	1,026,853	1,026,853	0.62%	0.62%	January 8, 2027
Zhuhai Rongqian Equity Investment L.P. (珠海融謙股權投資基金合夥企業(有限合夥))	138,764	138,764	0.08%	0.08%	January 8, 2027
Langma Twenty (Shenzhen) Venture Capital Center L.P.(朗瑪二十號(深圳)創業投資中心(有限合夥))	197,573	197,573	0.12%	0.12%	January 8, 2027
Langma Thirty-Two (Shenzhen) Venture Capital Center L.P.(朗瑪三十二號(深圳)創業投資中心(有限合夥))	136,075	136,075	0.08%	0.08%	January 8, 2027
Langma Ninety-Five (Shenzhen) Private Equity Venture Investment Fund Partnership (Limited Partnership)(朗瑪九十五號(深圳)私募創業投資基金合夥企業(有限合夥))	561,687	561,687	0.34%	0.34%	January 8, 2027
Langma Ninety-Six (Shenzhen) Private Equity Venture Investment Fund Partnership (Limited Partnership)(朗瑪九十六號(深圳)私募創業投資基金合夥企業(有限合夥))	240,723	240,723	0.15%	0.15%	January 8, 2027
Mr. William Wong (王興國)	895,091	895,091	0.54%	0.54%	January 8, 2027
Ningbo Boyuan Huizhi Enterprise Management Partnership (Limited Partnership) (寧波博遠匯智企業管理合夥企業(有限合夥))	848,299	848,299	0.51%	0.51%	January 8, 2027
Rixir Therapeutics, Limited	816,246	816,246	0.49%	0.49%	January 8, 2027
Zhuhai Hongtao Youxuan Equity Investment Partnership (LP)(珠海弘陶優選股權投資合夥企業(有限合夥))	697,248	697,248	0.42%	0.42%	January 8, 2027
Shenzhen Hongtao Jiaxin Equity Investment L.P (深圳弘陶嘉信股權投資合夥企業(有限合夥))	90,716	90,716	0.05%	0.05%	January 8, 2027
Mr. Claes Robert Wahlestedt	712,500	712,500	0.43%	0.43%	January 8, 2027

Name	Number of shares held in the Company subject to lock-up undertakings upon Listing	Number of H Shares held in the Company subject to lock-up undertakings upon Listing	% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing ⁽¹⁾	% of shareholding in the Company subject to lock-up undertakings upon Listing ⁽¹⁾	Last day subject to the lock-up undertakings ⁽²⁾
Mr. Joseph Wade Collard	712,500	712,500	0.43%	0.43%	January 8, 2027
Xinsu Ronghe (Changezhou) Environment Protection Investment Fund L.P. (新蘇融合(常州)環保投資基金(有限合夥))	613,092	613,092	0.37%	0.37%	January 8, 2027
Shenzhen Blue Ocean No. 1 Fund Management Investment Center L.P. (深圳藍海壹號基金管理投資中心)	554,287	554,287	0.33%	0.33%	January 8, 2027
Kunshan Shuangyu Investment Enterprise L.P. (昆山雙禺投資企業(有限合夥))	541,674	541,674	0.33%	0.33%	January 8, 2027
Worldstar Global Holdings Limited	501,506	501,506	0.30%	0.30%	January 8, 2027
Shenzhen Xinchuang Medical Private Equity Investment Fund Partnership (Limited Partnership) (深圳欣創醫合私募股權投資基金合夥企業(有限合夥))	401,205	401,205	0.24%	0.24%	January 8, 2027
Shanghai Bluestone Investment Co., Ltd. (上海藍石投資有限公司)	389,151	389,151	0.23%	0.23%	January 8, 2027
Shanghai Chuang Yuan Yuan Investment Management Co. Ltd. (上海創源垣投資管理有限公司)	382,268	382,268	0.23%	0.23%	January 8, 2027
Yantai Muxin Biopharmaceutical Health Industry Development Partnership (Limited Partnership) (煙台牟信生物醫藥健康產業發展合夥企業(有限合夥))	300,904	300,904	0.18%	0.18%	January 8, 2027
Ms. CHEN Chi Nga (陳之雅)	268,527	268,527	0.16%	0.16%	January 8, 2027
Mr. LI Xiaofeng (李曉峰)	267,470	267,470	0.16%	0.16%	January 8, 2027
Mr. MI Zhongye (宓仲業)	80,241	80,241	0.05%	0.05%	January 8, 2027
Subtotal	94,063,843	94,063,843	56.73%	56.73%	

Notes:

- (1) Taking into account the full exercise of the Offer Size Adjustment Option and before any exercise of the Over-allotment Option.
- (2) The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law.

Existing Shareholders (other than the Pre-IPO Investors as defined in the “History and Corporate Structure” section of the Prospectus)

Name	Number of shares held in the Company subject to lock-up undertakings upon Listing	Number of H Shares held in the Company subject to lock-up undertakings upon Listing	% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing ⁽¹⁾	% of shareholding in the Company subject to lock-up undertakings upon Listing ⁽¹⁾	Last day subject to the lock-up undertakings ⁽²⁾
Dr. LIANG Zicai (梁子才)	14,546,306	14,546,306	8.77%	8.77%	January 8, 2027
Kunshan Ruikong Enterprise Management Consulting L.P. (昆山瑞控企業管理諮詢合夥企業(有限合夥))	10,842,204	10,842,204	6.54%	6.54%	January 8, 2027
Kunshan Ruiman Enterprise Management Consulting L.P. (昆山瑞曼企業管理諮詢合夥企業(有限合夥))	5,539,551	5,539,551	3.34%	3.34%	January 8, 2027
Ms. MO Hua (莫華)	3,037,458	3,037,458	1.83%	1.83%	January 8, 2027
Prof. XI Zhen (席真)	2,847,150	2,847,150	1.72%	1.72%	January 8, 2027
Prof. ZHANG Lihe (張禮和)	1,898,100	1,898,100	1.14%	1.14%	January 8, 2027
Kunshan Ruiji Enterprise Management Consulting L.P. (昆山瑞技企業管理諮詢合夥企業(有限合夥))	1,428,498	1,428,498	0.86%	0.86%	January 8, 2027
Subtotal	40,139,267	40,139,267	24.21%	24.21%	

Notes:

- (1) Taking into account the full exercise of the Offer Size Adjustment Option and before any exercise of the Over-allotment Option.
- (2) The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law.

Cornerstone Investors

Name	Number of shares held in the Company subject to lock-up undertakings upon Listing	Number of H Shares held in the Company subject to lock-up undertakings upon Listing	% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing ⁽¹⁾	% of shareholding in the Company subject to lock-up undertakings upon Listing ⁽¹⁾	Last day subject to the lock-up undertakings ⁽²⁾
Arc Avenue Asset Management Pte. Ltd.	671,000	671,000	0.40%	0.40%	July 8, 2026
Bright Stone Holdings Limited	536,800	536,800	0.32%	0.32%	July 8, 2026
China Asset Management Co., Ltd.	2,013,200	2,013,200	1.21%	1.21%	July 8, 2026
Da Cheng International Asset Management Company Limited and Dacheng Fund Management Company Limited	2,013,200	2,013,200	1.21%	1.21%	July 8, 2026
Erik Selin Fastigheter Aktiebolag	1,342,000	1,342,000	0.81%	0.81%	July 8, 2026
Himension Fund	1,342,000	1,342,000	0.81%	0.81%	July 8, 2026
IvyRock Asset Management (HK) Limited	536,800	536,800	0.32%	0.32%	July 8, 2026
Mingxin Growth Ventures LS2 Limited	1,342,000	1,342,000	0.81%	0.81%	July 8, 2026
Springs Capital (Hong Kong) Limited	1,342,000	1,342,000	0.81%	0.81%	July 8, 2026
Taikang Life Insurance Co., Ltd.	1,610,400	1,610,400	0.97%	0.97%	July 8, 2026
Tenbagger Capital Nengxin), LP. (上海拾貝能信私募基金管理合夥企業(有限合夥)), Tenbagger Capital (Shanghai, Ziran), LP. (上海自然拾貝投資管理合夥企業(有限合夥)) and Huatai Capital Investment Limited	671,000	671,000	0.40%	0.40%	July 8, 2026
Subtotal	13,420,400	13,420,400	8.09%	8.09%	

Notes:

- (1) Taking into account the full exercise of the Offer Size Adjustment Option and before any exercise of the Over-allotment Option.
- (2) Each Cornerstone Investor shall not dispose of any of the Offer Shares acquired in the Global Offering at any time during the period of six months following the Listing Date pursuant to their respective Cornerstone Investment Agreement, save for certain limited circumstances, such as transfers to any of its wholly-owned subsidiaries who will be bound by the same obligations of the relevant Cornerstone Investor, including the lock-up period restriction. For details, please refer to the section headed “Cornerstone Investors – Restrictions on the Cornerstone Investors” of the Prospectus.

PLACEE CONCENTRATION ANALYSIS

Places	Number of H Shares Allocated	Allotment as % of International Offering (assuming the Over-allotment Option is exercised and new H Shares are issued)				Number of Shares held upon Listing	% of total issued share capital upon Listing (assuming the Over-allotment Option is exercised and new H Shares are issued)	
		Allotment as % of International Offering (assuming no exercise of the Over-allotment Option)	Allotment as % of total Offer Shares (assuming no exercise of the Over-allotment Option)	Allotment as % of total Offer Shares (assuming the Over-allotment Option is exercised and new H Shares are issued)	Allotment as % of total Offer Shares (assuming the Over-allotment Option is exercised and new H Shares are issued)		% of total issued share capital upon Listing (assuming no exercise of the Over-allotment Option)	% of total issued share capital upon Listing (assuming the Over-allotment Option is exercised and new H Shares are issued)
Top 1	2,013,200	6.98%	5.99%	6.37%	5.54%	2,013,200	1.21%	1.18%
Top 5	7,958,000	27.57%	23.68%	25.18%	21.89%	7,958,000	4.80%	4.67%
Top 10	14,507,200	50.26%	43.17%	45.89%	39.91%	14,507,200	8.75%	8.51%
Top 25	23,153,200	80.22%	68.90%	73.25%	63.69%	23,153,200	13.96%	13.58%

Notes

* Ranking of places is based on the number of H Shares allotted to the places.

H SHAREHOLDERS CONCENTRATION ANALYSIS

H Shareholders*	Number of H Shares allotted	Allotment as % of International Offering (assuming the Over-allotment Option is exercised and new H Shares are issued)				Number of H Shares held upon Listing	% of total issued H Shares capital upon Listing (assuming the Over-allotment Option is exercised and new H Shares are issued)		Number of Shares held upon Listing
		Allotment as % of International Offering (assuming no exercise of the Over-allotment Option)	Allotment as % of total Offer Shares (assuming no exercise of the Over-allotment Option)	Allotment as % of total Offer Shares (assuming the Over-allotment Option is exercised and new H Shares are issued)	Allotment as % of total Offer Shares (assuming the Over-allotment Option is exercised and new H Shares are issued)		% of total issued H Shares capital upon Listing (assuming no exercise of the Over-allotment Option)	% of total issued H Shares capital upon Listing (assuming the Over-allotment Option is exercised and new H Shares are issued)	
Top 1	0	0.00%	0.00%	0.00%	0.00%	40,139,267	24.21%	23.53%	40,139,267
Top 5	0	0.00%	0.00%	0.00%	0.00%	79,215,817	47.77%	46.45%	79,215,817
Top 10	0	0.00%	0.00%	0.00%	0.00%	105,533,652	63.65%	61.88%	105,533,652
Top 25	9,662,800	28.83%	24.76%	30.57%	26.58%	131,235,157	79.15%	76.95%	131,235,157

Notes

* Ranking of H Shareholders is based on the number of H Shares held by the H Shareholders upon Listing.

SHAREHOLDER CONCENTRATION ANALYSIS

Shareholders	Number of H Shares allotted	Allotment as % of International Offering (assuming the Over- allotment Option is no exercise of the Over- allotment Option)	Allotment as % of International Offering (assuming the Over- allotment Option is no exercise of the Over- allotment Option)	Allotment as % of total Offer Shares (assuming the Over- allotment Option is no exercise of the Over- allotment Option)	Allotment as % of total Offer Shares (assuming the Over- allotment Option is no exercise of the Over- allotment Option)	Number of H Shares held upon Listing	Number of Share held upon Listing	% of total issued share capital upon Listing (assuming the Over- allotment Option is no exercise of the Over- allotment Option)	% of total issued share capital upon Listing (assuming the Over- allotment Option is no exercise of the Over- allotment Option)
Top 1	0	0.00%	0.00%	0.00%	0.00%	40,139,267	40,139,267	24.21%	23.53%
Top 5	0	0.00%	0.00%	0.00%	0.00%	79,215,817	79,215,817	47.77%	46.45%
Top 10	0	0.00%	0.00%	0.00%	0.00%	105,533,652	105,533,652	63.65%	61.88%
Top 25	9,662,800	28.83%	24.76%	30.57%	26.58%	131,235,157	131,235,157	79.15%	76.95%

Notes

* Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholder upon Listing.

BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING

Subject to the satisfaction of the conditions set out in the Prospectus, a total of 42,771 valid applications made by the public will be conditionally allocated on the basis set out below:

NO. OF SHARES APPLIED FOR	NO. OF VALID APPLICATIONS	BASIS OF ALLOTMENT/BALLOT	APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF SHARES APPLIED FOR
POOL A			
200	26,796	457 out of 26,796 to receive 200 Shares	1.71%
400	2,121	72 out of 2,121 to receive 200 Shares	1.70%
600	1,068	54 out of 1,068 to receive 200 Shares	1.69%
800	3,408	227 out of 3,408 to receive 200 Shares	1.67%
1,000	749	62 out of 749 to receive 200 Shares	1.66%
1,200	211	21 out of 211 to receive 200 Shares	1.66%
1,400	175	20 out of 175 to receive 200 Shares	1.63%
1,600	434	56 out of 434 to receive 200 Shares	1.61%
1,800	344	50 out of 344 to receive 200 Shares	1.61%
2,000	1,897	304 out of 1,897 to receive 200 Shares	1.60%
3,000	586	141 out of 586 to receive 200 Shares	1.60%
4,000	481	154 out of 481 to receive 200 Shares	1.60%

**APPROXIMATE
PERCENTAGE
ALLOTTED OF
THE TOTAL
NO. OF SHARES
APPLIED FOR**

**NO. OF
SHARES
APPLIED FOR** **NO. OF
VALID
APPLICATIONS** **BASIS OF ALLOTMENT/BALLOT**

POOL A

5,000	319	127 out of 319 to receive 200 Shares	1.59%
6,000	304	145 out of 304 to receive 200 Shares	1.59%
7,000	180	100 out of 180 to receive 200 Shares	1.59%
8,000	212	135 out of 212 to receive 200 Shares	1.59%
9,000	142	101 out of 142 to receive 200 Shares	1.58%
10,000	978	775 out of 978 to receive 200 Shares	1.58%
20,000	680	200 Shares plus 397 out of 680 to receive additional 200 Shares	1.58%
30,000	234	400 Shares plus 88 out of 234 to receive additional 200 Shares	1.58%
40,000	156	600 Shares plus 21 out of 156 to receive additional 200 Shares	1.57%
50,000	120	600 Shares plus 110 out of 120 to receive additional 200 Shares	1.57%
60,000	93	800 Shares plus 65 out of 93 to receive additional 200 Shares	1.57%
70,000	53	1,000 Shares plus 26 out of 53 to receive additional 200 Shares	1.57%
80,000	88	1,200 Shares plus 23 out of 88 to receive additional 200 Shares	1.57%

41,829 Total number of Pool A successful applicants: 4,425

POOL B

90,000	466	600 Shares plus 106 out of 466 to receive additional 200 Shares	0.72%
100,000	151	600 Shares plus 89 out of 151 to receive additional 200 Shares	0.72%
150,000	87	1,000 Shares plus 33 out of 87 to receive additional 200 Shares	0.72%
200,000	73	1,400 Shares plus 13 out of 73 to receive additional 200 Shares	0.72%
250,000	34	1,600 Shares plus 33 out of 34 to receive additional 200 Shares	0.72%
300,000	18	2,000 Shares plus 14 out of 18 to receive additional 200 Shares	0.72%

**APPROXIMATE
PERCENTAGE
ALLOTTED OF
THE TOTAL
NO. OF SHARES
APPLIED FOR**

**NO. OF
SHARES
APPLIED FOR** **NO. OF
VALID
APPLICATIONS** **BASIS OF ALLOTMENT/BALLOT**

POOL B

350,000	11	2,400 Shares plus 6 out of 11 to receive additional 200 Shares	0.72%
400,000	21	2,800 Shares plus 7 out of 21 to receive additional 200 Shares	0.72%
500,000	13	3,400 Shares plus 12 out of 13 to receive additional 200 Shares	0.72%
600,000	6	4,200 Shares plus 3 out of 6 to receive additional 200 Shares	0.72%
700,000	9	5,000 Shares plus 1 out of 9 to receive additional 200 Shares	0.72%
800,000	6	5,600 Shares plus 4 out of 6 to receive additional 200 Shares	0.72%
900,000	2	6,400 Shares plus 1 out of 2 to receive additional 200 Shares	0.72%
1,000,000	11	7,000 Shares plus 10 out of 11 to receive additional 200 Shares	0.72%
1,374,400	34	9,800 Shares plus 10 out of 34 to receive additional 200 Shares	0.72%
<hr/>			
		942 Total number of Pool B successful applicants: 942	

As of the date of this announcement, the relevant subscription monies previously deposited in the designated nominee accounts have been remitted back to the accounts of all HKSCC participants. Investors should contact their relevant brokers for any inquiries.

COMPLIANCE WITH LISTING RULES AND GUIDANCE

The Directors confirm that, except for the Listing Rules that have been waived and/or in respect of which consent has been obtained, the Company has complied with the Listing Rules and guidance materials in relation to the placing, allotment and listing of the Company's H Shares.

The Directors confirm that, to the best of their knowledge, no rebate has been, directly or indirectly, provided by the Company, its controlling shareholder(s), directors or syndicate members to any placees or the public (as the case may be) and the consideration payable by them for each Offer Share of the Company subscribed for or purchased by them is the same as the Offer Price determined by the Company, in addition to any brokerage, AFRC transaction levy, SFC transaction levy and trading fee payable.

OTHER INFORMATION

Offer Size Adjustment Option

The Offer Size Adjustment Option has been fully exercised by the Overall Coordinators, pursuant to which the Company is issuing and allotting 4,123,000 additional Offer Shares, representing approximately 15% of the total number of Offer Shares initially available under the Global Offering, at the Offer Price. All of the additional Offer Shares that would be allotted and issued by the Company pursuant to the full exercise of the Offer Size Adjustment Option will be allocated to the International Offering. Accordingly, the total number of Offer Shares finally available under the Global Offering (taking into account the full exercise of the Offer Size Adjustment Option and before any exercise of the Over-allotment Option) that would be allotted and issued by the Company is 31,610,400 Offer Shares and the total issued share capital of the Company upon Listing (taking into account the full exercise of the Offer Size Adjustment Option and before any exercise of the Over-allotment Option) will be 165,813,510 Shares.

As a result of the above, the final number of Offer Shares under the International Offering is adjusted to 28,861,600 Shares, representing approximately 91.3% of the total number of Offer Shares under the Global Offering (assuming the Over-allotment Option is not exercised).

Placing to existing Shareholders and/or their close associates with prior consent under paragraph 1C(2) of the Placing Guidelines

Mr. Wong and Worldstar Global (collectively, the “Existing Shareholders as Placees”), and Blue Bay (the “Close Associate of Existing Shareholders as Placee”)

The Company has applied to the Stock Exchange, and the Stock Exchange has granted a consent under paragraph 1C(2) of the Placing Guidelines to permit the Company to allocate such Offer Shares in the International Offering to the Existing Shareholders as Placees and the Close Associate of Existing Shareholders as Placee set out below:

- (1) Mr. William WONG (王興國) (“**Mr. Wong**”), an existing Shareholder of the Company.
- (2) Worldstar Global Holdings Limited (“**Worldstar Global**”), an existing Shareholder of the Company.
- (3) Blue Bay Healthcare Anchor Fund SPC (“**Blue Bay**”) is a close associate of Shenzhen Blue Ocean No. 1 Fund Management Investment Center L.P. (深圳藍海壹號基金管理投資中心(有限合伙)) (“**Blue Ocean Investment**”), an existing Shareholder of the Company.

The allocation of Offer Shares to the Existing Shareholders as Placees and the Close Associate of Existing Shareholders as Placee is in compliance with all the conditions under the consent granted by the Stock Exchange, including but not limited to (i) the Company complies with Rules 19A.13A and 19A.13C of the Listing Rules, and (ii) no preference in allocation was given to the Existing Shareholders as Placees and the Close Associate of Existing Shareholders as Placee.

For details of the allocations of Offer Shares to close associates of existing Shareholders, please refer to the section headed “Allotment Results Details – International Offering – Allotees with Waivers/Consents Obtained” in this announcement.

Placing to connected clients with prior consent under paragraph 1C(1) of the Placing Guidelines

The Company has applied to the Stock Exchange for, and the Stock Exchange has granted a consent under paragraph 1C(1) of the Placing Guidelines to permit Tenbagger Nengxin, Tenbagger Ziran and Huatai Capital Investment Limited (in connection with Huatai OTC Swaps) to participate in the Global Offering as a cornerstone investor.

In addition, the Company has applied to the Stock Exchange, and the Stock Exchange has granted, a consent under paragraph 1C(1) of the Placing Guidelines to permit the Company to allocate certain Offer Shares in the International Offering to connected clients as placees. The allocation of Offer Shares to such connected clients is in compliance with all the conditions under the consent granted by the Stock Exchange.

Details of the placement to the connected clients above are set out below.

No.	Name of connected client	Name of connected distributor	Relationship with the connected distributor	Basis of holding securities	Number of Offer Shares subscribed	Ultimate beneficial owner of the Offer Shares allocated to the connected client	Percentage of the Offer Shares subscribed (assuming the Over-allotment Option is not exercised and taking into account full exercise of the offer size adjustment option)	Percentage of the issued Shares of the Company immediately upon completion of the Global Offering (assuming the Over-allotment Option is not exercised and taking into account full exercise of the offer size adjustment option)
1.	CICC Financial Trading Limited ("CICC FT") See Note 1 for further information of the ultimate clients of CICC FT.	China International Capital Corporation Hong Kong Securities Limited ("CICC")	CICC FT is a member of the same group as CICC.	Non-discretionary basis	725,600	See Note 1	2.30%	0.44%

No.	Name of connected client	Name of connected distributor	Relationship with the connected distributor	Basis of holding securities	Number of Offer Shares subscribed	Ultimate beneficial owner of the Offer Shares allocated to the connected client	Percentage of the Offer Shares subscribed (assuming the Over-allotment Option is not exercised and taking into account full exercise of the offer size adjustment option)	Percentage of the issued Shares of the Company immediately upon completion of the Global Offering (assuming the Over-allotment Option is not exercised and taking into account full exercise of the offer size adjustment option)
2.	<p>Guotai Junan Investments (Hong Kong) Limited (“GTJAI”)</p> <p>* Fullgoal Fund, Fullgoal HK and Haitong IAM (each as defined below); for their allocation information, see No. 6, No. 7 and No. 8 in this table.</p> <p>See Note 2 for further information of the ultimate clients of GTJAI.</p>	Guotai Junan Securities (Hong Kong) Limited (“GTJAS”)	GTJAI, together with Fullgoal Fund and Fullgoal HK, are members of the same group as GTJAS and Haitong International (as defined below).	Non-discretionary basis	274,600	See Note 2 and Note 5	0.87%	0.17%
3.	ABCI Asset Management Limited (“ABCI AM”)	ABCI Capital Limited and ABCI Securities Company Limited (“ABCI”)	ABCI AM is a member of the same group as ABCI.	Discretionary basis	5,800	See Note 4	0.00%	0.00%

No.	Name of connected client	Name of connected distributor	Relationship with the connected distributor	Basis of holding securities	Number of Offer Shares subscribed	Ultimate beneficial owner of the Offer Shares allocated to the connected client	Percentage of the Offer Shares subscribed (assuming the Over-allotment Option is not exercised and taking into account full exercise of the offer size adjustment option)	Percentage of the issued Shares of the Company immediately upon completion of the Global Offering (assuming the Over-allotment Option is not exercised and taking into account full exercise of the offer size adjustment option)
4.	ICBC UBS Asset Management Co., Ltd. (“ ICBC UBS ”)	ICBC International Securities Limited (“ ICBCI ”)	ICBC UBS and Invesco are members of the same group as ICBCI.	Discretionary basis	94,000	See Note 4	0.30%	0.06%
5.	Invesco Great Wall Fund Management Co., Ltd. (“ Invesco ”)			Discretionary basis	6,600		0.02%	0.00%
6.	Fullgoal Fund Management CO. LTD (“ Fullgoal Fund ”)	HAITONG INTERNATIONAL SECURITIES COMPANY LIMITED (“ Haitong International ”)	Fullgoal Fund, Fullgoal HK and Haitong IAM, together with GTJAI, are members of the same group as GTJAS and Haitong International.	Discretionary basis	100,600	See Note 2 and Note 5	0.32%	0.06%
7.	Fullgoal Asset management (HK) Limited (“ Fullgoal HK ”)			Discretionary basis	100,600		0.32%	0.06%

No.	Name of connected client	Name of connected distributor	Relationship with the connected distributor	Basis of holding securities	Number of Offer Shares subscribed	Ultimate beneficial owner of the Offer Shares allocated to the connected client	Percentage of the Offer Shares subscribed (assuming the Over-allotment Option is not exercised and taking into account full exercise of the offer size adjustment option)	Percentage of the issued Shares of the Company immediately upon completion of the Global Offering (assuming the Over-allotment Option is not exercised and taking into account full exercise of the offer size adjustment option)
8.	HAITONG INTERNATIONAL ASSET MANAGEMENT (HK) LIMITED (“Haitong IAM”) * GTJAI; for its allocation information, see No. 2 in this table.			Discretionary basis	6,600		0.02%	0.00%

Notes:

1. CICC FT and China International Capital Corporation Limited (“CICCL”) will enter into a series of cross border delta-one OTC swap transactions (collectively, the “**Zhonghe OTC Swaps**”) with each other and the ultimate clients (the “**CICC FT Ultimate Clients (Zhonghe)**”), pursuant to which CICC FT will hold the Offer Shares on a non-discretionary basis to hedge the Zhonghe OTC Swaps while the economic risks and returns of the underlying Offer Shares are passed to the CICC FT Ultimate Clients (Zhonghe), subject to customary fees and commissions. The Zhonghe OTC Swaps will be fully funded by the CICC FT Ultimate Clients (Zhonghe). To the best of CICC FT’s knowledge having made all reasonable inquiries, each of the CICC FT Ultimate Clients (Zhonghe) is an independent third party of CICC FT, CICC and the companies which are members of the same group of CICC, and the ultimate beneficial owner holding 30% or more interests in the of the CICC FT Ultimate Clients (Zhonghe) is Zhang Jingting (張敬庭).

CICC FT and CICCL will enter into a series of cross border delta-one OTC swap transactions (collectively, the “**Yongjin OTC Swaps**”) with each other and the ultimate clients (the “**CICC FT Ultimate Client (Yongjin)**”), pursuant to which CICC FT will hold the Offer Shares on a non-discretionary basis to hedge the Yongjin OTC Swaps while the economic risks and returns of the underlying Offer Shares are passed to the CICC FT Ultimate Client (Yongjin), subject to customary fees and commissions. The Yongjin OTC Swaps will be fully funded by the CICC FT Ultimate Client (Yongjin). To the best of CICC FT’s knowledge having made all reasonable inquiries, the CICC FT Ultimate Client (Yongjin) is an independent third party of CICC FT, CICC and the companies which are members of the same group of CICC, and the ultimate beneficial owners holding 30% or more interests in each of the of the CICC FT Ultimate Clients (Yongjin) are Wu Jialin (吳家麟) and Xie Xiaoyong (謝小勇), respectively.

CICC FT and CICCL will enter into a series of cross border delta-one OTC swap transactions (collectively, the “**Minghong OTC Swaps**”) with each other and the ultimate clients (the “**CICC FT Ultimate Client (Minghong)**”), pursuant to which CICC FT will hold the Offer Shares on a non-discretionary basis to hedge the Minghong OTC Swaps while the economic risks and returns of the underlying Offer Shares are passed to the CICC FT Ultimate Client (Minghong), subject to customary fees and commissions. The Minghong OTC Swaps will be fully funded by the CICC FT Ultimate Client (Minghong). To the best of CICC FT’s knowledge having made all reasonable inquiries, the CICC FT Ultimate Client (Minghong) is an independent third party of CICC FT, CICC and the companies which are members of the same group of CICC, and no single ultimate beneficial owner holds 30% or more interest in each of the CICC FT Ultimate Client (Minghong).

CICC FT and CICCL will enter into a series of cross border delta-one OTC swap transactions (collectively, the “**Wangzheng OTC Swaps**”) with each other and the ultimate clients (the “**CICC FT Ultimate Client (Wangzheng)**”), pursuant to which CICC FT will hold the Offer Shares on a non-discretionary basis to hedge the Wangzheng OTC Swaps while the economic risks and returns of the underlying Offer Shares are passed to the CICC FT Ultimate Client (Wangzheng), subject to customary fees and commissions. The Wangzheng OTC Swaps will be fully funded by the CICC FT Ultimate Client (Wangzheng). To the best of CICC FT’s knowledge having made all reasonable inquiries, the CICC FT Ultimate Client (Wangzheng) is an independent third party of CICC FT, CICC and the companies which are members of the same group of CICC, and the ultimate beneficial owner holding 30% or more interests in the of the CICC FT Ultimate Clients (Wangzheng) is Zhai Qin (瞿琴).

2. It is proposed that Guotai Junan Investments (Hong Kong) Limited (“**GTJAI**”) participates as placee to subscribe for the Offer Shares under the International Offering (the “**GTJAI Subscription**”). GTJAI is a member of the same group of companies as Guotai Junan Securities (Hong Kong) Limited (“**GTJAS**”) and is considered as a connected client of GTJAS pursuant to paragraph 1B(7) of the Placing Guidelines.

In relation to the GTJAI Subscription, GTJAI shall hold the Offer Shares for hedging purpose as the single underlying asset of several sets of back-to-back total return swap transaction (the “**GTHT Back-to-back TRS**”) to be entered into between GTJAI and Guotai Haitong Securities Co., Ltd. (the “**GTHT Onshore Parent**”) in connection with several total return swap orders (the “**GTHT Client TRS**”) to be entered into by GTHT Onshore Parent and several ultimate clients (the “**GTHT Onshore Ultimate Client**”), respectively. Such GTHT Client TRS is to be fully funded by the GTHT Onshore Ultimate Client. GTJAI will hold the Offer Shares on a non-discretionary basis for the purpose of hedging the economic exposure under the GTHT Back-to-back TRS and GTHT Client TRS only. During the tenor of the GTHT Client TRS, all economic returns of the Offer Shares will be passed to the GTHT Onshore Ultimate Clients and all economic losses shall be borne by the GTHT Onshore Ultimate Client, subject to the terms and conditions of the GTHT Back-to-back TRS and GTHT Client TRS, and GTJAI will not take part in any economic return or bear any economic loss in relation to the price of the Offer Shares. The GTHT Onshore Ultimate Client may request to redeem the Offer Shares at their own discretion, upon which GTJAI shall dispose of the Offer Shares and settle the GTHT Back-to-back TRS and GTHT Client TRS in cash in accordance with the terms and conditions of the GTHT Back-to-back TRS and GTHT Client TRS documents. Due to its internal policy, GTJAI will not exercise the voting right attaching to the Offer Shares during the tenor of the GTHT Back-to-back TRS and GTHT Client TRS.

To the best knowledge, information and belief of GTJAI after due enquiry, the GTHT Onshore Ultimate Clients and their respective ultimate beneficial owners holding 30% or more interest include:

- (i) Huang Shilin (黃世霖);
- (ii) Wang Jing (王靜);
- (iii) Sun Yuan (孫遠);
- (iv) Chuxin Li (李出新);
- (v) Yukai Shao (邵宇開);
- (vi) Wu Jiaqi (吳家麒);
- (vii) Xie Xiaoyong (謝小勇);
- (viii) Zeng Xiaojie (曾曉潔);
- (ix) ZHUANG TAO (莊濤);
- (x) CHEN QIN;
- (xi) CUI TONGKUI (崔同魁);
- (xii) XIAO MING (肖明); and
- (xiii) Guo Kai (郭鑄).

To the best knowledge of GTJAI after making all reasonable enquiries, (i) GTJAI has confirmed that, to the best of its knowledge, each of the GTHT Onshore Ultimate Clients and the ultimate beneficial owners holding 30% or more interest of the GTHT Onshore Ultimate Clients listed above is an independent third party of GTJAI, GTJAS and the companies which are members of the same group of companies as GTJAS, and (ii) GTJAI is not a collective investment scheme which is not authorised by the SFC nor is expected to hold the Offer Shares on behalf of such scheme.

- 3. ABCI AM intends to hold the Offer Shares in its capacity as manager managing investment portfolios on behalf of underlying investors who are independent third parties on a discretionary basis.
- 4. ICBC UBS intends to hold the Offer Shares in its capacity as manager managing investment portfolios on behalf of underlying investors who are independent third parties on a discretionary basis.

Invesco intends to hold the Offer Shares in its capacity as manager managing investment portfolios on behalf of underlying investors who are independent third parties on a discretionary basis.

- 5. Fullgoal Fund intends to hold the Offer Shares in its capacity as manager managing investment portfolios on behalf of underlying investors who are independent third parties on a discretionary basis.

Fullgoal HK intends to hold the Offer Shares in its capacity as manager managing investment portfolios on behalf of underlying investors who are independent third parties on a discretionary basis.

Haitong IAM intends to hold the Offer Shares in its capacity as manager managing investment portfolios on behalf of underlying investors who are independent third parties on a discretionary basis.

DISCLAIMERS

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and Hong Kong Securities Clearing Company Limited (“HKSCC”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States.

The Offer Shares are being offered and sold (1) solely to qualified institutional buyers as defined in Rule 144A under the U.S. Securities Act pursuant to an exemption from registration under the U.S. Securities Act and (2) outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus dated December 31, 2025 issued by Suzhou Ribio Life Science Co., Ltd. for detailed information about the Global Offering described below before deciding whether or not to invest in the H Shares thereby being offered.

** Potential investors of the Offer Shares should note that the Joint Sponsors and the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the paragraph headed “Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on January 9, 2026).*

PUBLIC FLOAT AND FREE FLOAT

Immediately after the completion of the Global Offering, 110,900,415 H Shares, representing approximately 66.88% of the issued share capital of our Company (before any exercise of the Over-allotment Option) will count towards the public float. Therefore, the number of H shares held in public hands is higher than the prescribed percentage of H Shares required to be held in public hands under Rule 19A.13A(1) of the Listing Rules, satisfying the minimum percentage requirement in compliance with Rule 19A.13A(1) of the Listing Rules, representing 15.61% of H Shares to be held in public hands with the expected market value of HK\$1.5 billion at the time of Listing, based on the Offer Price of HK\$57.97 per H Share.

All the existing shareholders of the Company are subject to a lock-up period of 12 months following the Listing Date pursuant to the applicable PRC laws and all the cornerstone investors are subject to a lock-up period of six months following the Listing Date. The Offer Shares to be subscribed by all the other investors participating in the Global Offering are not subject to any disposal restriction. Excluding the Offer Shares to be allocated to the cornerstone investors that are subject to a lock-up period of six months following the Listing Date, the Company's H Shares to be counted towards the free float upon Listing will be 18,190,000 Shares. Based on the Offer Price of HK\$57.97 per H Share, the Company will satisfy the free float requirement under Rule 19A.13C(1)(b) of the Listing Rules

The Directors confirm that, immediately following completion of the Global Offering: (i) the Shares will be held by at least 300 Shareholders at the time of Listing, in compliance with Rule 8.08(2) of the Listing Rules; (ii) the three largest public Shareholders will not hold more than 50% of the H Shares held in public hands at the time of Listing, in compliance with Rules 8.08(3) and 8.24 of the Listing Rules; (iii) no placee will, individually, be placed more than 10% of the enlarged issued share capital of the Company immediately after the Global Offering; and (iv) there will not be any new substantial Shareholder (as defined in the Listing Rules) immediately after the Global Offering.

COMMENCEMENT OF DEALINGS

The H Share certificates will only become valid evidence of title at 8:00 a.m. (Hong Kong time) on Friday, January 9, 2026, provided that (i) the Global Offering has become unconditional in all respects, and (ii) the right of termination described in the section headed "Underwriting – Underwriting Arrangements and Expenses – Hong Kong Underwriting Agreement – Grounds for termination" in the Prospectus has not been exercised. Investors who trade H Shares prior to the receipt of H Share certificates or the H Share certificates becoming valid evidence of title do so entirely at their own risk.

Assuming that the Global Offering becomes unconditional at or before 8:00 a.m. (Hong Kong time) on Friday, January 9, 2026,, it is expected that dealings in the H Shares on the Stock Exchange will commence at 9:00 a.m. on Friday, January 9, 2026,. The H Shares will be traded in board lots of 200 H Shares each and the stock code of the H Shares will be 6938.

By order of the Board
Suzhou Ribo Life Science Co., Ltd.
Dr. LIANG Zicai

Chairman, Executive Director and Chief Executive Officer

Hong Kong, January 8, 2026

Directors of the Company named in the application to which this announcement relates are Dr. LIANG Zicai, Dr. GAN Liming and Dr. ZHANG Hongyan as executive directors, Dr. QI Fei, Mr. LI Dongfang and Mr. LI Yuhui as non-executive directors, and Dr. YU Xuefeng, Mr. MA Chaosong and Mr. WANG Ruiping as independent non-executive directors.